NovaBridge Biosciences (NBP) Net Income towards Common Stockholders (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Net Income towards Common Stockholders of -$72.9 million for Q4 2025, down 312.02% year-over-year from $34.4 million in Q4 2024, and down 967.05% quarter-over-quarter from -$6.8 million in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 312.02% year-over-year to -$72.9 million; the TTM figure through Dec 2025 stood at -$88.3 million (down 1366.5% YoY), while the FY2024 annual figure was $27.5 million, up 113.3% from the prior year.
- Net Income towards Common Stockholders retreated to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $34.4 million in Q4 2024 and bottomed at -$72.9 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$11.5 million across 3 years, with a median of -$6.2 million in 2025.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 66.68% in 2025 and fell as far as 4233946.15% in 2025.
- NovaBridge Biosciences' Net Income towards Common Stockholders stood at -$33.3 million in 2023, then jumped by 203.33% to $34.4 million in 2024, then sank by 312.02% to -$72.9 million in 2025.
- Business Quant data shows NBP's Net Income towards Common Stockholders at -$72.9 million in Q4 2025, -$6.8 million in Q3 2025, and -$5.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -88.34 Mn |
| Sep 30, 2025 | 8.65 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -22.23 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | 25.13 Mn |
| Mar 31, 2024 | -16.32 Mn |
| Dec 31, 2023 | -66.61 Mn |
| Sep 30, 2023 | -33.26 Mn |
| Jun 30, 2023 | -61.47 Mn |
| Dec 31, 2020 | 157.16 Mn |
| Sep 30, 2020 | 1.77 Mn |
| Dec 31, 2019 | -54.14 Mn |
| Sep 30, 2019 | -35.10 Mn |